Johnson & Johnson Innovative Medicine

We’re restoring the true meaning of healthcare—developing advanced treatments and smarter and less invasive solutions for today’s most complex diseases. See how we're connecting the best of Health&Care for every patient and provider. https://lnkd.in/eW-mXA49

New research, conducted in collaboration with The Sheffield University and published by Pulmonary Vascular Research Institute (PVRI), describes the clinical characteristics, healthcare resource utilization and costs, health-related quality of life, and survival for patients with #PAH, reinforcing the importance of our commitment to the PH community. Learn more about the outcomes here: https://bit.ly/4cOj2T8 #JNJCardiopulmonary #PulmonaryCirculation #PCJournal

#News: Johnson & Johnson reported Second Quarter 2024 earnings results recently We achieved significant Innovative Medicine pipeline milestones and strengthened our portfolio of marketed medicines in meaningful ways with new approvals.    Together with our partners, we remain committed to developing treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. Explore our results here: https://lnkd.in/eriyG_zy #JNJ #Earnings 

Today, we completed the acquisition of Yellow Jersey Therapeutics, gaining ownership of NM26 and building our leadership in atopic dermatitis. Learn more: https://bit.ly/3XY8Tyz #JNJImmunology

Calling all entrepreneurs, innovators and academics! Join Johnson & Johnson for the first webinar in our Innovation Ignited series on July 24: Conversations in Precision Medicine - Digital Diagnostics for Neuroscience   If you’ve ever wondered how J&J leverages strategic collaborations to lead the way in healthcare innovation, this webinar series is the perfect opportunity to find out.  RSVP today:   https://lnkd.in/gcFxNYXm 

Thank you to the European Academy of Neurology for offering us the opportunity to collaborate with other industry professionals who share the common goal of reimagining the treatment landscape for patients with neuroscience autoantibody-driven diseases. Our ongoing research aims to provide patients with symptom-free remission through deep autoantibody reduction. #JNJNeuroscience #JNJImmunology

The Johnson & Johnson team attended the 7th World Symposium on Pulmonary Hypertension - an incredible gathering of experts in the field! It was great to learn about the latest developments, share exciting data from our activities and connect with this passionate community. #WSPH2024

Over the next few days, our team looks forward to presenting at #EAN2024, and learning from other industry experts. Hear from Katie Abouzahr, M.D., about how our research is addressing unmet needs in generalized myasthenia gravis (gMG). Discover how we are pushing the boundaries of research with the hope to one day deliver innovative and transformative treatments for neuroscience autoantibody-driven diseases: https://bit.ly/4arSp5p    #JNJNeuroscience #JNJImmunology

At Johnson & Johnson, we believe every person should be valued and protected, regardless of their sexuality and gender identity. We’re committed to the LGBTQIA+ community and we look forward to increasing inclusivity for all community members and allies, not just during Pride Month, but all year round. #Pride

Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and may also cause damage to connective tissues and blood vessels over time. Today, for #WorldSclerodermaDay, Johnson & Johnson is joining the community to raise awareness for those living with the disease and the 1 in 10 patients who will develop pulmonary arterial hypertension (PAH). As a company, we encourage everyone to come together today and join the movement in supporting this #RareDisease.